Abbott Laboratories (NYSE:ABT) Chairman Miles D. White sold 276,886 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total transaction of $15,065,367.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Abbott Laboratories (NYSE:ABT) traded down $0.05 during trading hours on Friday, hitting $54.64. 5,087,300 shares of the stock were exchanged, compared to its average volume of 6,594,714. The firm has a market capitalization of $95,141.25, a price-to-earnings ratio of 22.68, a PEG ratio of 2.05 and a beta of 1.06. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 52 week low of $37.90 and a 52 week high of $56.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The company had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. Abbott Laboratories’s revenue was up 28.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.59 earnings per share. research analysts anticipate that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were issued a dividend of $0.265 per share. The ex-dividend date was Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.94%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 83.47%.

ABT has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a research note on Tuesday, October 31st. Royal Bank Of Canada reissued a “buy” rating and issued a $55.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Jefferies Group reaffirmed a “buy” rating and set a $65.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 19th. Bank of America reaffirmed a “buy” rating and set a $60.00 target price (up previously from $56.00) on shares of Abbott Laboratories in a research note on Wednesday, October 4th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Abbott Laboratories has an average rating of “Buy” and an average price target of $56.81.

Large investors have recently modified their holdings of the company. Heritage Trust Co lifted its holdings in Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the period. Tributary Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at $106,000. Winfield Associates Inc. lifted its holdings in Abbott Laboratories by 3.9% in the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after buying an additional 89 shares during the period. Thompson Davis & CO. Inc. lifted its holdings in Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the period. Finally, JFS Wealth Advisors LLC lifted its holdings in Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after buying an additional 2,094 shares during the period. Institutional investors own 71.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/08/insider-selling-abbott-laboratories-abt-chairman-sells-276886-shares-of-stock.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.